<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6171930</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0205119</article-id><article-id pub-id-type="publisher-id">PONE-D-18-14219</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Mutation</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Identification and Analysis</subject><subj-group><subject>Mutation Detection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Extraction techniques</subject><subj-group><subject>RNA extraction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Biological Databases</subject><subj-group><subject>Mutation Databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject><subj-group><subject>Mutation Databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Sequencing techniques</subject><subj-group><subject>RNA sequencing</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Sequencing techniques</subject><subj-group><subject>RNA sequencing</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>HIV-1C proviral DNA for detection of drug resistance mutations</article-title><alt-title alt-title-type="running-head">HIV-1C proviral DNA</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huruy</surname><given-names>Kahsay</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2862-0175</contrib-id><name><surname>Mulu</surname><given-names>Andargachew</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Liebert</surname><given-names>Uwe Gerd</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Melanie</surname><given-names>Maier</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Institute of Virology, Leipzig University, Leipzig, Germany</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Paraskevis</surname><given-names>Dimitrios</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>National and Kapodistrian University of Athens, GREECE</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>andargachewmulu@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>4</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>10</issue><elocation-id>e0205119</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Huruy et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Huruy et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0205119.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Using HIV proviral DNA as a template may be suitable for initial detection of transmitted drug resistance mutations (TDRMs) as it is easy to handle and less expensive compared to RNA. However, existing literatures which are mainly focused on HIV-1B subtypes DNA extracted from PBMCs revealed controversial findings ranging from the detection of significantly lower or higher mutations in proviral DNA compared to historic viral RNA. Thus, to verify whether viral RNA or proviral DNA has improved sensitivity in detecting transmitted genotypic drug resistance mutations paired viral RNA and proviral DNA (which is directly extracted from stored whole blood) samples were tested from Ethiopian antiretroviral naive HIV-1C infected subjects.</p></sec><sec id="sec002"><title>Methods</title><p>In the present comparative study the frequency of TDR mutations was assessed in paired samples of viral RNA and proviral DNA (extracted directly from stored whole blood) of HIV-1C infected treatment na&#x000ef;ve patients and interpreted using the 2009 WHO drug resistance surveillance mutation lists, Stanford University drug resistance data base and International Antiviral Society-USA mutation lists.</p></sec><sec id="sec003"><title>Results</title><p>High agreement in rate of TDR between the two compartments was observed using the WHO mutation lists. While mutations G190A and E138A were concurrently found in both compartments, others such as G73S on PR and A62V, M184I, M230I on RT were identified in proviral DNA only. All signature mutations seen in viral RNA were not missed in proviral DNA.</p></sec><sec id="sec004"><title>Conclusions</title><p>The concordance of major genotype drug resistance mutation between RNA and proviral DNA in treatment na&#x000ef;ve patients suggests that proviral DNA might be an alternative approaches for an initial assessment of drug resistance prior to initiation of antiretroviral therapy using the WHO mutations lists in resource-limited countries. However, the clinical importance of TDRMs observed only in proviral DNA in terms of being a risk factor for virologic failure and whether they limit future treatment options needs additional investigation using more sensitive sequencing approaches such as Next Generation Sequencing (NGS).</p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="5"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The nucleotide sequences are available at the National Centre for Biotechnology Information (NCBI), USA GenBank (accession numbers KJ807732 to KJ807772 for proviral DNA and KJ807649 to KJ807689 for viral RNA).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The nucleotide sequences are available at the National Centre for Biotechnology Information (NCBI), USA GenBank (accession numbers KJ807732 to KJ807772 for proviral DNA and KJ807649 to KJ807689 for viral RNA).</p></notes></front><body><sec id="sec005"><title>Background</title><p>Since the introduction of antiretroviral therapy (ART), the relative rates of morbidity and mortality from acquired immunodeficiency syndrome have been reduced significantly [<xref rid="pone.0205119.ref001" ref-type="bibr">1</xref>]. However, the clinical benefits of ART are jeopardized by the emergence of drug-resistant HIV-1 strains [<xref rid="pone.0205119.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0205119.ref003" ref-type="bibr">3</xref>]. The currently available ART is directed against virus-specific enzymes as well as the processes of attachment and entry into cells and are not curative nor eradicate HIV infection, as latent infection is established through the integration of double-stranded proviral DNA into the host cell which is essential during HIV life cycle [<xref rid="pone.0205119.ref004" ref-type="bibr">4</xref>]. The proviral DNA archives viral variants and preserves them until transcription and translation is initiated in these cells again. These cells, at least temporarily not producing virus, represent a barrier to viral eradication and it is inherently difficult to specifically target and remove such cells [<xref rid="pone.0205119.ref005" ref-type="bibr">5</xref>]. Accordingly, proviral DNA has been investigated as an additional source of information on HIV-1 resistance analysis [<xref rid="pone.0205119.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0205119.ref011" ref-type="bibr">11</xref>]. Simultaneous analysis of viral RNA and proviral DNA apparently increases the sensitivity of TDR detection and testing of proviral DNA may also be important for monitoring treatment outcomes [<xref rid="pone.0205119.ref012" ref-type="bibr">12</xref>]. However, existing literatures which are mainly focused on HIV-1B subtypes revealed controversial findings ranging from the detection of significantly lower [<xref rid="pone.0205119.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0205119.ref008" ref-type="bibr">8</xref>] or higher [<xref rid="pone.0205119.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0205119.ref011" ref-type="bibr">11</xref>] mutations in proviral DNA compared to historic viral RNA to a high level of genotype concordance between RNA and proviral DNA in newly diagnosed viremic patients [<xref rid="pone.0205119.ref013" ref-type="bibr">13</xref>&#x02013;<xref rid="pone.0205119.ref015" ref-type="bibr">15</xref>] and in a viremic patients under ART [<xref rid="pone.0205119.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0205119.ref015" ref-type="bibr">15</xref>]. Moreover, most of the above comparative studies were conducted on DNA extracted from PBMCs which is more labor intensive and expensive to prepare and requires at least -70&#x000b0;C cold storage which is not available in most laboratories of the developing countries.</p><p>Thus, to verify whether viral RNA or proviral DNA has improved sensitivity in detecting transmitted genotypic drug resistance mutations paired viral RNA and proviral DNA (which is directly extracted from stored whole blood) samples were tested from antiretroviral naive HIV-1C infected subjects from Ethiopian where HIV-1 transmitted drug resistance is increasing [<xref rid="pone.0205119.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0205119.ref021" ref-type="bibr">21</xref>].</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><p>Four ml of whole blood was collected in EDTA-containing tubes from 41 ART na&#x000ef;ve HIV-1C infected patients from Northwest Ethiopia (Gondar University and Metema Hospitals) during January to March 2010. For preservation of cells, blood samples were immediately mixed with ethylene and propylene glycol (EPG, Sigma Chemical Co., Gaithersburg, Md, USA; final EPG concentration 20%) [<xref rid="pone.0205119.ref022" ref-type="bibr">22</xref>] and stored at -20 &#x000b0;C. CD4<sup>+</sup> T-cell count was performed on fresh whole blood by flow cytometry (FACScount system, Becton Dickinson, San Jose, CA, USA) following the manufacturer&#x02019;s specifications. Details of patient&#x02019;s recruitment and management has been described elsewhere [<xref rid="pone.0205119.ref020" ref-type="bibr">20</xref>].</p><p>Extraction of plasma RNA, HIV-1 viral load determination and HIV-1 viral genome amplification and sequencing of protease codons 1&#x02013;99 and reverse transcriptase codons 1&#x02013;331 was done as described previously [<xref rid="pone.0205119.ref017" ref-type="bibr">17</xref>]. DNA was manually extracted from the cellular fraction according to published protocol with minor modifications [<xref rid="pone.0205119.ref023" ref-type="bibr">23</xref>]. Briefly, PBS (phosphate buffered saline) containing 0.1% NP-40 was added at a ratio of 1:5 to 1 ml of whole blood supplemented with EPG and centrifuged at 3,000 x g for 5 min. The pellet was re-suspended in PBS (1 ml containing 5% SDS) and incubated at 37 &#x000b0;C for 30 min. Thereafter, equal volume of lyses buffer (8 M urea, 0.3 M NaCl, 10 mM EDTA, 10 mMTris-HCl pH 7.5) was added, followed by further incubation at 37 &#x000b0;C for 30 min. Total DNA was manually extracted by phase extraction using organic solvent, followed by ethanol precipitation.</p><p>Amplification of HIV-1 proviral DNA was done using the same protocol as for viral RNA [<xref rid="pone.0205119.ref017" ref-type="bibr">17</xref>] but omitting the RT step. PCR final products for viral RNA and proviral DNA were purified using Wizard SV Gel and PCR Clean-up kit (Promega, Madison, WI, USA). The purified PCR products were sequenced using the fluorescent dideoxy-terminator method and the ABI Prism 3100 genetic analyser (Applied Biosystem, Foster City, CA, USA). FASTA files were analysed using Stanford University HIV-1 Sequence Database (<ext-link ext-link-type="uri" xlink:href="http://hivdb.stanford.edu">http://hivdb.stanford.edu</ext-link>), which contains a computer assisted interpretation of mutational profiles providing five levels of inferred drug resistance. All except the fully susceptible HIV-1 sequences were considered as resistant in the analysis of the present study. Each sequence from both compartments was also analysed using WHO mutation lists (<ext-link ext-link-type="uri" xlink:href="http://cpr.stanford.edu.cpr.cgi">http://cpr.stanford.edu.cpr.cgi</ext-link>) and the updated 2017 International Antiviral Society (IAS) mutation lists [<xref rid="pone.0205119.ref024" ref-type="bibr">24</xref>]. All sequences obtained from both, viral RNA and proviral DNA, were confirmed using the Rega HIV-1 subtyping tool, version 2.0 (<ext-link ext-link-type="uri" xlink:href="http://www.bioafrica.net/subtypetool">http://www.bioafrica.net/subtypetool</ext-link>). Phylogenetic tree was constructed by the neighbour-joining method using data generated from the <italic>pol</italic> region (RT and PR genes) of all viral RNA and proviral DNA sequences. The reliability of the branching orders was assessed using the bootstrap approach with MEGA version 5 [<xref rid="pone.0205119.ref025" ref-type="bibr">25</xref>]. Seventeen reference strains, 9 representing HIV-1C and 8 representing non-B subtypes were included for comparison. The nucleotide sequences were deposited at the National Centre for Biotechnology Information (NCBI), USA GenBank (accession numbers KJ807732 to KJ807772 for proviral DNA and KJ807649 to KJ807689 for viral RNA).</p><p>Statistical analysis was carried out using SPSS software, version 17.0 (SPSS, Chicago, II., USA). Mean and standard deviation (SD) were computed for the different variables. A <italic>P</italic>-value less than 0.05 was considered statistically significant and 95% confidence intervals (CI) were computed by GraphPad Prism software version 5 (San Diego, CA, USA).</p></sec><sec id="sec007"><title>Ethics approval and consent to participate</title><p>All of the protocols using human specimens including written consent were approved by The University of Gondar Ethical Review Committee (RPO 55/258/2001) and written consent was obtained from all of the subjects.</p></sec><sec sec-type="results" id="sec008"><title>Results</title><p>The characteristics of the study subjects (n = 41) are summarized in <xref rid="pone.0205119.t001" ref-type="table">Table 1</xref>. Thirty-three were in age group 26&#x02013;45 years and 24 (58.5%) were men. Only eight patients (19.5%) had more than 200 CD4<sup>+</sup> T cells per ml. The mean &#x000b1; SD of viral load (log<sub>10</sub> copies/ml) and hemoglobin values (g/dl) of the patients was 4.76 &#x000b1; 0.60 and 10.98 &#x000b1; 2.5, respectively. Female gender but not age, baseline CD4 cell count and hemoglobin values was significantly associated with drug resistance [odds ratio 6.22, p = 0.020].</p><table-wrap id="pone.0205119.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0205119.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of patients.</title></caption><alternatives><graphic id="pone.0205119.t001g" xlink:href="pone.0205119.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Total numberofpatients</th><th align="center" rowspan="1" colspan="1">41</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Men</td><td align="center" rowspan="1" colspan="1">24 (58.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Women</td><td align="center" rowspan="1" colspan="1">17 (41.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;21&#x02013;25</td><td align="center" rowspan="1" colspan="1">5 (12.2%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;26&#x02013;35</td><td align="center" rowspan="1" colspan="1">23 (56.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;36&#x02013;45</td><td align="center" rowspan="1" colspan="1">10 (24.4%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x02265; 46</td><td align="center" rowspan="1" colspan="1">3 (7.3%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Mean &#x000b1; SD of hemoglobin (g/dl)</td><td align="center" rowspan="1" colspan="1">10.98 &#x000b1; 2.5</td></tr><tr><td align="justify" rowspan="1" colspan="1">CD4 cell count (cells per mm<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;&#x0003c; 50</td><td align="center" rowspan="1" colspan="1">11 (26.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;50&#x02013;99</td><td align="center" rowspan="1" colspan="1">11 (26.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;100&#x02013;199</td><td align="center" rowspan="1" colspan="1">11 (26.8%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;200&#x02013;320</td><td align="center" rowspan="1" colspan="1">8 (19.5%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Mean &#x000b1; SD of HIV RNA viral load (log<sub>10</sub> copies per ml)</td><td align="center" rowspan="1" colspan="1">4.76 &#x000b1; 0.60</td></tr></tbody></table></alternatives></table-wrap><p>The <italic>pol</italic> consensus sequences consisting of 1,261 nucleotides were analyzed to assess the similarity between the viral RNA and proviral DNA (<xref ref-type="fig" rid="pone.0205119.g001">Fig 1</xref>). For all patients the infecting virus was identified as HIV-1C. The phylogenetic tree reveals a high genetic similarity between viral RNA and proviral DNA. However, in four paired samples (G7, M31, M42, and M65) RNA and DNA sequences clustered at different branches.</p><fig id="pone.0205119.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0205119.g001</object-id><label>Fig 1</label><caption><title>The neighbour-joining phylogenetic tree depicting the relationship between viral RNA (indicated with letter and number) and proviral DNA (indicated with letter, number and PD) from 41 treatment na&#x000ef;ve patients in Northwest Ethiopia.</title><p>Patients who developed HIV-1 drug resistance (black circles for HIV-1 proviral DNA and black rectangles for HIV-1 RNA) also indicated. For comparison, 17 reference strains (empty circles) from the Los Alamos HIV-1 database representing subtype C with GenBank accession numbers U46016 (Ethiopia C), AF067155 (India C), AF110980 (Botswana C), AF361874 (Tanzania C), AY772699 (S Africa C), U52953 (Brazil C), AF286233 (Israel C), AF286230 (China C), AF286225 (Zambia C), and A,B,D,F,G,H,J,K subtypes are included. The nucleotide sequences were submitted to GenBank (accession number: KJ807732&#x02014;KJ807772 and KJ807649&#x02014;KJ807689 for proviral DNA and viral RNA, respectively).</p></caption><graphic xlink:href="pone.0205119.g001"/></fig><p>Overall, sequence profiles of both RNA and proviral DNA were concordant in 83% (34/41) of the patients. Thirty patients had wild type genotype in both PR and RT region of the pol genome from both viral RNA and proviral DNA; eleven patients (26.8%, <xref rid="pone.0205119.t002" ref-type="table">Table 2</xref>) had a mutant type from both compartments conferring transmitted drug resistance, of which in four patients mutations were concurrently detected both in RNA and proviral DNA; in two patients mutations were only found in viral RNA (patients ID G043 and G174) and in five patients drug resistance mutations occurred only in proviral DNA (patients ID G020, G168, G269, M072 and M092). Despite differences between the different algorithms, in all algorithms DNA is more sensitive to detect drug resistance mutations and none of the signature mutations found in viral RNA was missed in proviral DNA. High agreement in rate of TDR between HIV RNA and proviral DNA was observed using the WHO drug resistance surveillance mutation lists with coefficient of agreement (<xref rid="pone.0205119.t003" ref-type="table">Table 3</xref>). The prevalence of TDR is summarized in <xref rid="pone.0205119.t002" ref-type="table">Table 2</xref>. The overall rate of TDR to at least one drug class using WHO mutation lists, Stanford University Algorithm database and the IAS mutation lists was 19.5% (8/41 patients, CI 10.0&#x02013;34.3%), 22.0% (9/41, CI 11.8&#x02013;36.9%) and 26.8% (11/41; CI 15.6&#x02013;42.1%), respectively (<xref rid="pone.0205119.t003" ref-type="table">Table 3</xref>). Out of the 5 patients with drug resistant associated mutations in proviral DNA, three had &#x02265;2 APOBEC3G/F signature mutations (M184I and M230I) in reverse transcriptase region with G-to-A mutations. However, since we do not know the role of of APOBEC3G/F activity on future virological outcomes (particlualry in HIV-1C isolates), we prefered to count these mutations in the rate of TDR.</p><table-wrap id="pone.0205119.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0205119.t002</object-id><label>Table 2</label><caption><title>Characteristics of patients with transmitted drug resistant strains.</title></caption><alternatives><graphic id="pone.0205119.t002g" xlink:href="pone.0205119.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="3" colspan="1">Code</th><th align="left" rowspan="3" colspan="1">Age (years)</th><th align="justify" rowspan="3" colspan="1">Gender</th><th align="left" rowspan="3" colspan="1">CD4<sup>+</sup> count (cells/mm<sup>3</sup>)</th><th align="left" rowspan="3" colspan="1">Viral load (log<sub>10</sub> copies/ml)</th><th align="center" colspan="6" rowspan="1">Drug resistance associated mutations</th></tr><tr><th align="center" colspan="2" rowspan="1">PI</th><th align="center" colspan="2" rowspan="1">NRTI</th><th align="center" colspan="2" rowspan="1">NNRTI</th></tr><tr><th align="left" rowspan="1" colspan="1">Viral RNA</th><th align="left" rowspan="1" colspan="1">Proviral DNA</th><th align="left" rowspan="1" colspan="1">Viral RNA</th><th align="left" rowspan="1" colspan="1">Proviral DNA</th><th align="center" rowspan="1" colspan="1">Viral RNA</th><th align="left" rowspan="1" colspan="1">Proviral DNA</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">G014</td><td align="justify" rowspan="1" colspan="1">35</td><td align="justify" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">253</td><td align="char" char="." rowspan="1" colspan="1">5.65</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">G190A<xref ref-type="table-fn" rid="t002fn002">*</xref><xref ref-type="table-fn" rid="t002fn003"><sup>+</sup></xref><xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td><td align="center" rowspan="1" colspan="1">G190A</td></tr><tr><td align="justify" rowspan="1" colspan="1">G020</td><td align="justify" rowspan="1" colspan="1">31</td><td align="justify" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">104</td><td align="char" char="." rowspan="1" colspan="1">4.34</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">G73S<xref ref-type="table-fn" rid="t002fn002">*</xref><xref ref-type="table-fn" rid="t002fn003"><sup>+</sup></xref></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M230I<xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td></tr><tr><td align="justify" rowspan="1" colspan="1">G043</td><td align="justify" rowspan="1" colspan="1">44</td><td align="justify" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">62</td><td align="char" char="." rowspan="1" colspan="1">4.31</td><td align="center" rowspan="1" colspan="1">M46I<xref ref-type="table-fn" rid="t002fn002">*</xref><xref ref-type="table-fn" rid="t002fn003"><sup>+</sup></xref><xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="justify" rowspan="1" colspan="1">G086</td><td align="justify" rowspan="1" colspan="1">55</td><td align="justify" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">4.82</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">E138A<xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td><td align="center" rowspan="1" colspan="1">E138A</td></tr><tr><td align="justify" rowspan="1" colspan="1">G168</td><td align="justify" rowspan="1" colspan="1">30</td><td align="justify" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">75</td><td align="char" char="." rowspan="1" colspan="1">4.92</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M46I</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M230I</td></tr><tr><td align="justify" rowspan="1" colspan="1">G174</td><td align="justify" rowspan="1" colspan="1">30</td><td align="justify" rowspan="1" colspan="1">Femae</td><td align="center" rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">4.52</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">G190E<xref ref-type="table-fn" rid="t002fn002">*</xref><xref ref-type="table-fn" rid="t002fn003"><sup>+</sup></xref></td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="justify" rowspan="1" colspan="1">G183</td><td align="justify" rowspan="1" colspan="1">27</td><td align="justify" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">4.49</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">E138G<xref ref-type="table-fn" rid="t002fn003"><sup>+</sup></xref><xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td><td align="center" rowspan="1" colspan="1">E138AG<xref ref-type="table-fn" rid="t002fn003"><sup>+</sup></xref><xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td></tr><tr><td align="justify" rowspan="1" colspan="1">G269</td><td align="justify" rowspan="1" colspan="1">35</td><td align="justify" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">5.58</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">A62V<xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="justify" rowspan="1" colspan="1">M072</td><td align="justify" rowspan="1" colspan="1">26</td><td align="justify" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">18</td><td align="char" char="." rowspan="1" colspan="1">4.94</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M184I<xref ref-type="table-fn" rid="t002fn002">*</xref><xref ref-type="table-fn" rid="t002fn003"><sup>+</sup></xref><xref ref-type="table-fn" rid="t002fn004"><sup>#</sup></xref></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M230I</td></tr><tr><td align="justify" rowspan="1" colspan="1">M086</td><td align="justify" rowspan="1" colspan="1">28</td><td align="justify" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">201</td><td align="char" char="." rowspan="1" colspan="1">4.11</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">G190A</td><td align="center" rowspan="1" colspan="1">G190A</td></tr><tr><td align="justify" rowspan="1" colspan="1">M092</td><td align="justify" rowspan="1" colspan="1">30</td><td align="justify" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">91</td><td align="char" char="." rowspan="1" colspan="1">4.41</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M184I</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M230I</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>PI-protease inhibitor; NRTI-nucleotide reverse transcriptase inhibitor; NNRTI-non- nucleotide reverse transcriptase inhibitor; (-) no drug resistant mutations detected;</p></fn><fn id="t002fn002"><p><sup>(*)</sup> mutations found in WHO mutation lists;</p></fn><fn id="t002fn003"><p><sup>(+)</sup> mutations according to Stanford University drug resistance database;</p></fn><fn id="t002fn004"><p><sup>(#)</sup> mutations found in IAS lists.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0205119.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0205119.t003</object-id><label>Table 3</label><caption><title>TDR frequency according to different algorithms.</title></caption><alternatives><graphic id="pone.0205119.t003g" xlink:href="pone.0205119.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Number of patients (relative frequency)</th></tr><tr><th align="justify" rowspan="1" colspan="1">TDR found in</th><th align="center" rowspan="1" colspan="1">WHO</th><th align="center" rowspan="1" colspan="1">Stanford</th><th align="center" rowspan="1" colspan="1">IAS</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Viral RNA</td><td align="center" rowspan="1" colspan="1">4 (9.8%)</td><td align="center" rowspan="1" colspan="1">5 (12.2%)</td><td align="center" rowspan="1" colspan="1">5 (12.2%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Proviral DNA</td><td align="center" rowspan="1" colspan="1">6 (14.6%)</td><td align="center" rowspan="1" colspan="1">7 (17.1%)</td><td align="center" rowspan="1" colspan="1">9 (22.0%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Overall TDR</td><td align="center" rowspan="1" colspan="1">8 (19.5%)</td><td align="center" rowspan="1" colspan="1">9 (22.0%)</td><td align="center" rowspan="1" colspan="1">11 (26.8%)</td></tr></tbody></table></alternatives></table-wrap><p>Four out of eleven patients (G20, G168, M72 and M92) had two TDR in their proviral DNA representing multi-drug resistance (<xref rid="pone.0205119.t002" ref-type="table">Table 2</xref>). The rest seven patients (17.1%) harboured a virus with one mutation each either in viral RNA or proviral DNA or both compartments. The profile of TDR was: in four patients mutations (i.e. G190A, E138A/G) were found concurrently both in viral RNA and proviral DNA, in two patients resistance mutations (M46I and G190E) were detected only in viral RNA, and in five patients archived transmitted drug resistance mutations (M230I, G73S, M184I, M46I, and A62V) in proviral DNA were identified. TDR appeared to be higher in patients with CD4<sup>+</sup> cell count &#x0003c; 100 cells/mm<sup>3</sup> (72.7%) and in patients who were in the age group of 26&#x02013;35 years (81.8%, <xref rid="pone.0205119.t002" ref-type="table">Table 2</xref>). However, these differences were not statistically significant (<italic>P</italic>&#x0003e; 0.05). TDR to NNRTI was identified in 22.0% (9/41) of patients from both, viral RNA and proviral DNA, and in three patient&#x02019;s resistance mutations to PIs. NRTIs related mutations M184I and A62V were only found in proviral DNA (<xref rid="pone.0205119.t002" ref-type="table">Table 2</xref>). HIV-1 proviral DNA from sample G168 had two archived transmitted drug resistance mutations (M46I and M230I) the same is true for G020 (G73S and M230I). Please note that, E138A is a polymorphic change depending on subtype and could occur in 0.5% to 5% of viruses from treatment naive patients. However, its presence reduces ETR and RPV susceptibility by about 2-fold and hence the presence of E138A prior to therapy may reduce the antiviral activity of RPV. Thus, E138A is considered as a TDR mutation.</p><p>The abundance of polymorphisms (<xref rid="pone.0205119.t004" ref-type="table">Table 4</xref>) at known drug resistance positions were significantly higher in proviral DNA (24.4% (10/41); 95% CI 13.7&#x02013;29.5%) than in viral RNA (17.1% (7/41); 95% CI, 8.2&#x02013;31.6%). Polymorphic changes at the drug resistance sites were more frequent in PR region than in the RT region in both compartments where 80% (8/10) and 85.7% (6/7) were identified in plasma RNA and proviral DNA, respectively. Positions V82I (PR) and A98S (RT) were most common polymorphic alterations in both compartments (<xref rid="pone.0205119.t005" ref-type="table">Table 5</xref>).</p><table-wrap id="pone.0205119.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0205119.t004</object-id><label>Table 4</label><caption><title>Occurrence of polymorphisms at drug resistance sites.</title></caption><alternatives><graphic id="pone.0205119.t004g" xlink:href="pone.0205119.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">Antiretroviral drug class</th></tr><tr><th align="justify" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">PI</th><th align="center" rowspan="1" colspan="1">NRTI</th><th align="center" rowspan="1" colspan="1">NNRTI</th><th align="center" rowspan="1" colspan="1">Sum</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Viral RNA</td><td align="center" rowspan="1" colspan="1">1 (2.4%)</td><td align="center" rowspan="1" colspan="1">2 (4.9%)</td><td align="center" rowspan="1" colspan="1">4 (9.8%)</td><td align="center" rowspan="1" colspan="1">7 (17.1%)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Proviral DNA</td><td align="center" rowspan="1" colspan="1">2 (4.9%)</td><td align="center" rowspan="1" colspan="1">3 (7.3%)</td><td align="center" rowspan="1" colspan="1">5 (12.2%)</td><td align="center" rowspan="1" colspan="1">10 (24.4%)</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0205119.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0205119.t005</object-id><label>Table 5</label><caption><title>Frequency of polymorphisms at drug resistance positions in HIV viral RNA and proviral DNA in treatment na&#x000ef;ve patients.</title></caption><alternatives><graphic id="pone.0205119.t005g" xlink:href="pone.0205119.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Location</th><th align="center" colspan="2" rowspan="1">PI mutations</th><th align="center" rowspan="1" colspan="1">Location</th><th align="center" colspan="2" rowspan="1">NRTI mutations</th><th align="center" rowspan="1" colspan="1">Location</th><th align="center" colspan="2" rowspan="1">NNRTI mutations</th></tr><tr><th align="center" rowspan="1" colspan="1">PR</th><th align="left" rowspan="1" colspan="1">Viral RNA</th><th align="left" rowspan="1" colspan="1">Proviral DNA</th><th align="center" rowspan="1" colspan="1">RT</th><th align="left" rowspan="1" colspan="1">Viral RNA</th><th align="left" rowspan="1" colspan="1">Proviral DNA</th><th align="center" rowspan="1" colspan="1">RT</th><th align="left" rowspan="1" colspan="1">Viral RNA</th><th align="left" rowspan="1" colspan="1">Proviral DNA</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">L23</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M41</td><td align="center" rowspan="1" colspan="1">1(I)</td><td align="center" rowspan="1" colspan="1">1(I)</td><td align="center" rowspan="1" colspan="1">A98</td><td align="center" rowspan="1" colspan="1">7(S)</td><td align="center" rowspan="1" colspan="1">8(S)</td></tr><tr><td align="center" rowspan="1" colspan="1">L24</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">A62</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">L100</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">D30</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">K65</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">K101</td><td align="center" rowspan="1" colspan="1">1(R)</td><td align="center" rowspan="1" colspan="1">1(R)</td></tr><tr><td align="center" rowspan="1" colspan="1">V32</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">D67</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">K103</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">L33</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">T69</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">1(S)</td><td align="center" rowspan="1" colspan="1">V106</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">M46</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">K70</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">V108</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">I47</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">L74</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">V179</td><td align="center" rowspan="1" colspan="1">2(I)</td><td align="center" rowspan="1" colspan="1">3(I)</td></tr><tr><td align="center" rowspan="1" colspan="1">G48</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2(R)<xref ref-type="table-fn" rid="t005fn002">*</xref></td><td align="center" rowspan="1" colspan="1">V75</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Y181</td><td align="center" rowspan="1" colspan="1">1(F)</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">I50</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">F77</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Y188</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">F53</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Y115</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">G190</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2(R)</td></tr><tr><td align="center" rowspan="1" colspan="1">I54</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">F116</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">P225</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">G73</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">V118</td><td align="center" rowspan="1" colspan="1">1(I)</td><td align="center" rowspan="1" colspan="1">1(I)</td><td align="center" rowspan="1" colspan="1">F227</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">L76</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Q151</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">M230</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">V82</td><td align="center" rowspan="1" colspan="1">5(I)</td><td align="center" rowspan="1" colspan="1">5(I)</td><td align="center" rowspan="1" colspan="1">M184</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">E138</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">I84</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">L210</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">P236</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">1(PT)</td></tr><tr><td align="center" rowspan="1" colspan="1">N88</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">T215</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">L90</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">K219</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>PR-protease; RT-reverse transcriptase; NRTI-nucleoside reverse transcriptase inhibitor; NNRTI- non-NRTI; (-) no polymorphisms detected;</p></fn><fn id="t005fn002"><p><sup>(*)</sup>-number of mutation (mutant amino acid)</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions" id="sec009"><title>Discussion</title><p>In the present study, 83% (34/41) of the patient&#x02019;s had concordant sequence profile in determining transmitted drug resistance from both RNA and proviral DNA and those major mutations conferring transmitted drug resistance in RNA (the gold-standard template for HIV drug resistance testing as it reflects the virus that is actively reproducing) were also concordantly detected in proviral DNA consistent with recent finding [<xref rid="pone.0205119.ref013" ref-type="bibr">13</xref>] and suggest that proviral DNA could be used as an alternative template for determining transmitted drug resistance particularly in developing countries considering the fact that: i) RNA genotyping requires RNA extraction and storage at least at -70&#x000b0;C which in most cases is not available in developing countries; ii) RNA needs reverse-transcription which is costly and RNA could easily be degraded before reverse-transcription, impairing amplification and sequencing quality. On the other hand, unlike other studies which used PBMCs, this study used whole blood preserved in 20% EG and stored at -20&#x000b0;C, followed by DNA extraction subjected to direct amplification and sequencing shows the durability and long term stability of whole blood proviral DNA and thus using of proviral DNA directly from whole blood as a template for determining transmitted drug resistance is less expensive. However, there was difference between the RNA and proviral DNA in drug resistance associated mutations for NRTIs (0 vs 3 samples) which could represent archival genetic resistance which may be transmitted or re-emerge with treatment [<xref rid="pone.0205119.ref014" ref-type="bibr">14</xref>].</p><p>The inconsistencies between plasma viral RNA and peripheral blood mononuclear cell proviral DNA in HIV-1 drug resistant strains have been reported from treatment naive individuals ranging from the detection of significantly lower [<xref rid="pone.0205119.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0205119.ref008" ref-type="bibr">8</xref>] or higher [<xref rid="pone.0205119.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0205119.ref011" ref-type="bibr">11</xref>] mutations in proviral DNA compared to historic viral RNA. Although, the clinical relevance of transmitted drug resistance mutation in proviral DNA among these treatment na&#x000ef;ve patients is not defined in the current study, they may not affect the clinical out-comes of ART in short period of time [<xref rid="pone.0205119.ref026" ref-type="bibr">26</xref>]. However, whether these transmitted drug resistance mutation in proviral DNA will be definite risk factors for virologic failure and therefore limiting future treatment options in the course of infection with HAART needs additional investigation. Indeed, it has been shown that the long term persistence of archived drug resistant HIV-1 proviral DNA could undermine the capability of targeted treatment(s) and represents the potential resistance pattern in future [<xref rid="pone.0205119.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0205119.ref027" ref-type="bibr">27</xref>].</p><p>The observed lower abundance of TDR in viral RNA than proviral DNA (14.6% vs 22%) could be conceivably a result of the reversion over time of HIV-1 quasispecies resistant to HAART [<xref rid="pone.0205119.ref028" ref-type="bibr">28</xref>] being archived in proviral DNA [<xref rid="pone.0205119.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0205119.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0205119.ref011" ref-type="bibr">11</xref>]. The occurrence of hypermutation in 3 out of 5 sequence of the reverse transcriptase region of the proviral DNA is consistent with recent studies [<xref rid="pone.0205119.ref029" ref-type="bibr">29</xref>].</p><p>Four out of the 41 paired samples from both compartments did not show a tight proximity relation to each other suggesting that circulating strains produced in the plasma compartment could arise from sources other than circulating infected leukocytes [<xref rid="pone.0205119.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0205119.ref030" ref-type="bibr">30</xref>]. Most of the studies on the comparison of HIV-1 drug resistance in cell-free and cell-containing compartments were undertaken in HAART treated subjects [<xref rid="pone.0205119.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0205119.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0205119.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0205119.ref033" ref-type="bibr">33</xref>]. The available few data among treatment na&#x000ef;ve patients [<xref rid="pone.0205119.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0205119.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0205119.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0205119.ref011" ref-type="bibr">11</xref>] were exclusively conducted in HIV-1B isolates. To the best of our knowledge this is the first report among HIV-1C isolates which compares the profile of transmitted drug resistance mutation from paired RNA and proviral DNA templates. The 22.0% of TDR to NNRTIs matches well with earlier observations where NNRTI associated drug resistance mutations were found more frequently than mutations against other ART classes both in HIV-1B [<xref rid="pone.0205119.ref034" ref-type="bibr">34</xref>]and non B subtypes [<xref rid="pone.0205119.ref035" ref-type="bibr">35</xref>, <xref rid="pone.0205119.ref036" ref-type="bibr">36</xref>]. The profiles of TDR mutations between viral RNA and proviral DNA in the present study are variable in such a way that TDRs mutations conferring resistance to RTIs and PIs were identified more frequently in proviral DNA than viral RNA consistent with previous studies among treatment na&#x000ef;ve patients [<xref rid="pone.0205119.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0205119.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0205119.ref037" ref-type="bibr">37</xref>]. In contrast to these findings, several other studies showed comparable prevalence of TDRs from RNA and proviral DNA among treatment na&#x000ef;ve patients [<xref rid="pone.0205119.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0205119.ref039" ref-type="bibr">39</xref>] and ART experienced and failing patients with history of TDR [<xref rid="pone.0205119.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0205119.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0205119.ref027" ref-type="bibr">27</xref>].</p></sec><sec id="sec010"><title>Limitations</title><p>The data has an obvious limitations including small sample size with few detected drug resistance mutation. Although there is technical improvements in the amplifcation of drug resiatnce genome using direct whole blood as a template, the technical improvment over sequencing is limitted. It would have been interesting to evaluate the use of more sensitive sequencing approaches such as Next Generation Sequencing (NGS) that might partially explain the observed differences between viral DNA and plasma RNA. Thus, the observd small mutation might be due to the low sensitivity nature of of the Sanger sequencing approach. Furthermore, as the nature the study was cross sectional, the clinical importance of the mutations observed only in proviral DNA in terms of being risk factors for virologic failure and whether limits future treatment options is not addressed. Nevertheless, with all these limitation we concluded the points below (Conclusions).</p></sec><sec sec-type="conclusions" id="sec011"><title>Conclusion</title><p>In summary, as sequencing of HIV-1 proviral DNA which is extracted directly from stored whole blood detects all signature mutations observed in RNA and is less expensive and technically easier to perform compared to RNA, determining TDR using the WHO drug resistance surveillance mutation list from proviral DNA could be an alternative approaches especially in resource limited countries. However, the clinical importance of transmitted drug resistance mutations observed only in proviral DNA in terms of being risk factors for virologic failure and limits future treatment options in future needs additional investigation using more sensitive sequencing approaches such as Next Generation Sequencing (NGS).</p></sec></body><back><ack><p>We thank Dr. Ute Brinckmann and Ms Sandra Bergs from the Institute of Virology for their excellent technical support and our appreciation also goes to all study participants.</p></ack><ref-list><title>References</title><ref id="pone.0205119.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Imaz</surname><given-names>A</given-names></name>, <name><surname>Falco</surname><given-names>V</given-names></name>, <name><surname>Ribera</surname><given-names>E</given-names></name>. <article-title>Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice</article-title>. <source>AIDS Rev</source>
<year>2011</year>: <volume>13</volume>(<issue>3</issue>):<fpage>180</fpage>&#x02013;<lpage>93</lpage>. <?supplied-pmid 21799536?><pub-id pub-id-type="pmid">21799536</pub-id></mixed-citation></ref><ref id="pone.0205119.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Frentz</surname><given-names>D</given-names></name>, <name><surname>Boucher</surname><given-names>CAB</given-names></name>, <name><surname>van de Vijver</surname><given-names>DAMC</given-names></name>. <article-title>Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world</article-title>. <source>AIDS Rev</source>
<year>2012</year>: <volume>14</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>27</lpage>. <?supplied-pmid 22297501?><pub-id pub-id-type="pmid">22297501</pub-id></mixed-citation></ref><ref id="pone.0205119.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Wainberg</surname><given-names>MA</given-names></name>, <name><surname>Brenner</surname><given-names>BG</given-names></name>. <article-title>Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs</article-title>. <source>Viruses</source>
<year>2011</year> 1: <volume>2</volume>(<issue>11</issue>):<fpage>2493</fpage>&#x02013;<lpage>508</lpage>.</mixed-citation></ref><ref id="pone.0205119.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Alexaki</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Wigdahl</surname><given-names>B</given-names></name>. <article-title>Cellular reservoirs of HIV-1 and their role in viral persistence</article-title>. <source>Curr HIV Res</source>
<year>2008</year>: <volume>6</volume>(<issue>5</issue>):<fpage>388</fpage>&#x02013;<lpage>400</lpage>. <?supplied-pmid 18855649?><pub-id pub-id-type="pmid">18855649</pub-id></mixed-citation></ref><ref id="pone.0205119.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Turriziani</surname><given-names>O</given-names></name>, <name><surname>Andreoni</surname><given-names>M</given-names></name>, <name><surname>Antonelli</surname><given-names>G</given-names></name>. <article-title>Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection</article-title>. <source>Clin Microbiol Infect</source>
<year>2010</year>: <volume>16</volume>(<issue>10</issue>):<fpage>1518</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2010.03329.x</pub-id>
<?supplied-pmid 20673260?><pub-id pub-id-type="pmid">20673260</pub-id></mixed-citation></ref><ref id="pone.0205119.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Bon</surname><given-names>I</given-names></name>, <name><surname>Gibellini</surname><given-names>D</given-names></name>, <name><surname>Borderi</surname><given-names>M</given-names></name>, <name><surname>Alessandrini</surname><given-names>F</given-names></name>, <name><surname>Vitone</surname><given-names>F</given-names></name>, <name><surname>Schiavone</surname><given-names>P</given-names></name>
<etal>et al</etal>
<article-title>Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients</article-title>. <source>J Clin Virol</source>
<year>2007</year>: <volume>38</volume>(<issue>4</issue>):<fpage>313</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2006.12.018</pub-id>
<?supplied-pmid 17306618?><pub-id pub-id-type="pmid">17306618</pub-id></mixed-citation></ref><ref id="pone.0205119.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>d&#x02019;Ettorre</surname><given-names>G</given-names></name>, <name><surname>Zaffiri</surname><given-names>L</given-names></name>, <name><surname>Ceccarelli</surname><given-names>G</given-names></name>, <name><surname>Mastroianni</surname><given-names>CM</given-names></name>, <name><surname>Vullo</surname><given-names>V</given-names></name>. <article-title>The role of HIV-DNA testing in clinical practice</article-title>. <source>New Microbiol</source>
<year>2010</year>: <volume>33</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>11</lpage>. <?supplied-pmid 20402409?><pub-id pub-id-type="pmid">20402409</pub-id></mixed-citation></ref><ref id="pone.0205119.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Kabamba-Mukadi</surname><given-names>B</given-names></name>, <name><surname>Duquenne</surname><given-names>A</given-names></name>, <name><surname>Henrivaux</surname><given-names>P</given-names></name>, <name><surname>Musuamba</surname><given-names>F</given-names></name>, <name><surname>Ruelle</surname><given-names>J</given-names></name>, <name><surname>Yombi</surname><given-names>J</given-names></name>
<etal>et al</etal>
<article-title>HIV-1 proviral resistance mutations: usefulness in clinical practice</article-title>. <source>HIV Med</source>
<year>2010</year>: <volume>11</volume>(<issue>8</issue>):<fpage>483</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-1293.2009.00814.x</pub-id>
<?supplied-pmid 20163482?><pub-id pub-id-type="pmid">20163482</pub-id></mixed-citation></ref><ref id="pone.0205119.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Parisi</surname><given-names>SG</given-names></name>, <name><surname>Boldrin</surname><given-names>C</given-names></name>, <name><surname>Cruciani</surname><given-names>M</given-names></name>, <name><surname>Nicolini</surname><given-names>G</given-names></name>, <name><surname>Cerbaro</surname><given-names>I</given-names></name>, <name><surname>Manfrin</surname><given-names>V</given-names></name>
<etal>et al</etal>
<article-title>Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients</article-title>. <source>J Clin Microbiol</source>
<year>2007</year>: <volume>45</volume>(<issue>6</issue>):<fpage>1783</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00056-07</pub-id>
<?supplied-pmid 17442799?><pub-id pub-id-type="pmid">17442799</pub-id></mixed-citation></ref><ref id="pone.0205119.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Turriziani</surname><given-names>O</given-names></name>, <name><surname>Bucci</surname><given-names>M</given-names></name>, <name><surname>Stano</surname><given-names>A</given-names></name>, <name><surname>Scagnolari</surname><given-names>C</given-names></name>, <name><surname>Bellomi</surname><given-names>F</given-names></name>, <name><surname>Fimiani</surname><given-names>C</given-names></name>
<etal>et al</etal>
<article-title>Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals</article-title>. <source>J Acquir Immune Defic Syndr</source>
<year>2007</year>: <volume>44</volume>(<issue>5</issue>):<fpage>518</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e3180315515</pub-id>
<?supplied-pmid 17224845?><pub-id pub-id-type="pmid">17224845</pub-id></mixed-citation></ref><ref id="pone.0205119.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Vicenti</surname><given-names>I</given-names></name>, <name><surname>Razzolini</surname><given-names>F</given-names></name>, <name><surname>Saladini</surname><given-names>F</given-names></name>, <name><surname>Romano</surname><given-names>L</given-names></name>, <name><surname>Zazzi</surname><given-names>M</given-names></name>. <article-title>Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects</article-title>. <source>Clin Infect Dis</source>
<year>2007</year>: <volume>44</volume>(<issue>12</issue>):<fpage>1657</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1086/518287</pub-id>
<?supplied-pmid 17516412?><pub-id pub-id-type="pmid">17516412</pub-id></mixed-citation></ref><ref id="pone.0205119.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>GQ</given-names></name>, <name><surname>Swenson</surname><given-names>LC</given-names></name>, <name><surname>Poon</surname><given-names>AFY</given-names></name>, <name><surname>Martin</surname><given-names>JN</given-names></name>, <name><surname>Hatano</surname><given-names>H</given-names></name>, <name><surname>Deeks</surname><given-names>SG</given-names></name>
<etal>et al</etal>
<article-title>Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing</article-title>. <source>PLoS One</source>
<year>2012</year>: <volume>7</volume>(<issue>9</issue>):<fpage>e46181</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0046181</pub-id>
<?supplied-pmid 23049972?><pub-id pub-id-type="pmid">23049972</pub-id></mixed-citation></ref><ref id="pone.0205119.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Derache</surname><given-names>A</given-names></name>, <name><surname>Shin</surname><given-names>H-S</given-names></name>, <name><surname>Balamane</surname><given-names>M</given-names></name>, <name><surname>White</surname><given-names>E</given-names></name>, <name><surname>Israelski</surname><given-names>D</given-names></name>, <name><surname>Klausner</surname><given-names>JD</given-names></name>, <etal>et al</etal>
<article-title>HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program</article-title>. <source>PLoS ONE</source>
<year>2015</year>: <volume>10</volume>(<issue>1</issue>): <fpage>e0117430</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0117430</pub-id>
<?supplied-pmid 25635815?><pub-id pub-id-type="pmid">25635815</pub-id></mixed-citation></ref><ref id="pone.0205119.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Banks</surname><given-names>L</given-names></name>, <name><surname>Gholamin</surname><given-names>S</given-names></name>, <name><surname>White</surname><given-names>E</given-names></name>, <name><surname>Zijenah</surname><given-names>L</given-names></name>, <name><surname>Katzenstein</surname><given-names>DA</given-names></name>. <article-title>Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1</article-title>. <source>J AIDS Clin Res</source>
<year>2012</year>: <volume>3</volume>(<issue>2</issue>):<fpage>141</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 23019537?><pub-id pub-id-type="pmid">23019537</pub-id></mixed-citation></ref><ref id="pone.0205119.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Demetriou</surname><given-names>VL</given-names></name>, <name><surname>van de Vijver</surname><given-names>DAMC</given-names></name>, <name><surname>Kousiappa</surname><given-names>I</given-names></name>, <name><surname>Balotta</surname><given-names>C</given-names></name>, <name><surname>Clotet</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Cellular HIV-1 DNA Levels in Drug Sensitive Strains Are Equivalent to Those in Drug Resistant Strains in Newly-Diagnosed Patients in Europe</article-title>. <source>PLoS ONE</source>
<year>2010</year>: <volume>5</volume>(<issue>6</issue>): <fpage>e10976</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0010976</pub-id>
<?supplied-pmid 20544014?><pub-id pub-id-type="pmid">20544014</pub-id></mixed-citation></ref><ref id="pone.0205119.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Kassu</surname><given-names>A</given-names></name>, <name><surname>Fujino</surname><given-names>M</given-names></name>, <name><surname>Matsuda</surname><given-names>M</given-names></name>, <name><surname>Nishizawa</surname><given-names>M</given-names></name>, <name><surname>Ota</surname><given-names>F</given-names></name>, <name><surname>Sugiura</surname><given-names>W</given-names></name>. <article-title>Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia</article-title>. <source>AIDS Res Hum Retroviruses</source>
<year>2007</year>: <volume>23</volume>(<issue>4</issue>):<fpage>564</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2006.0270</pub-id>
<?supplied-pmid 17451346?><pub-id pub-id-type="pmid">17451346</pub-id></mixed-citation></ref><ref id="pone.0205119.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Mulu</surname><given-names>A</given-names></name>, <name><surname>Lange</surname><given-names>T</given-names></name>, <name><surname>Liebert</surname><given-names>UG</given-names></name>, <name><surname>Maier</surname><given-names>M</given-names></name>. <article-title>Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia</article-title>. <source>BMC Infect Dis</source>
<year>2014</year>: <volume>14</volume>(<issue>1</issue>):<fpage>158</fpage>.<pub-id pub-id-type="pmid">24655349</pub-id></mixed-citation></ref><ref id="pone.0205119.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Abegaz</surname><given-names>WE</given-names></name>, <name><surname>Grossman</surname><given-names>Z</given-names></name>, <name><surname>Wolday</surname><given-names>D</given-names></name>, <name><surname>Ram</surname><given-names>D</given-names></name>, <name><surname>Kaplan</surname><given-names>J</given-names></name>, <name><surname>Sibide</surname><given-names>K</given-names></name>
<etal>et al</etal>
<article-title>Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia</article-title>. <source>AntivirTher</source>
<volume>13</volume>
<issue>Suppl</issue>
<year>2008</year>: <volume>2</volume>:<fpage>89</fpage>&#x02013;<lpage>94</lpage>.</mixed-citation></ref><ref id="pone.0205119.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Abdissa</surname><given-names>A</given-names></name>, <name><surname>Yilma</surname><given-names>D</given-names></name>, <name><surname>Fonager</surname><given-names>J</given-names></name>, <name><surname>Audelin</surname><given-names>AM</given-names></name>, <name><surname>Christensen</surname><given-names>LH</given-names></name>, <name><surname>Olsen</surname><given-names>MF</given-names></name>
<etal>et al</etal>
<article-title>Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia</article-title>. <source>BMC Infect Dis</source>
<year>2014</year>: <volume>14</volume>:<fpage>181</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2334-14-181</pub-id>
<?supplied-pmid 24708645?><pub-id pub-id-type="pmid">24708645</pub-id></mixed-citation></ref><ref id="pone.0205119.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Huruy</surname><given-names>K</given-names></name>, <name><surname>Maier</surname><given-names>M</given-names></name>, <name><surname>Mulu</surname><given-names>A</given-names></name>, <name><surname>Liebert</surname><given-names>UG</given-names></name>. <article-title>Limited increase in primary HIV-1C drug resistance mutations in treatment na&#x000ef;ve individuals in Ethiopia</article-title>.<source>J Med Virol</source>
<year>2015</year>: <volume>87</volume>(<issue>6</issue>):<fpage>978</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.24110</pub-id> Epub 2015 Feb <?supplied-pmid 25649964?><pub-id pub-id-type="pmid">25649964</pub-id></mixed-citation></ref><ref id="pone.0205119.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Mulu</surname><given-names>A</given-names></name>, <name><surname>Maier</surname><given-names>M</given-names></name>, <name><surname>Liebert</surname><given-names>UG</given-names></name>. <article-title>Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study</article-title>. <source>PLoS One</source>
<year>2015</year>: <volume>10</volume>(<issue>10</issue>):<fpage>e0141318</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0141318</pub-id>
<?supplied-pmid 26512902?><pub-id pub-id-type="pmid">26512902</pub-id></mixed-citation></ref><ref id="pone.0205119.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Leal-Klevezas</surname><given-names>DS</given-names></name>, <name><surname>Martinez-Vazquez</surname><given-names>IO</given-names></name>, <name><surname>Cuevas-Hernandez</surname><given-names>B</given-names></name>, <name><surname>Martinez-Soriano</surname><given-names>JP</given-names></name>
<article-title>Antifreeze solution improves DNA recovery by preserving the integrity of pathogen-infected blood and other tissues</article-title>. <source>Clin Diagn Lab Immunol</source>
<year>2000</year>: <volume>7</volume>(<issue>6</issue>):<fpage>945</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">11063503</pub-id></mixed-citation></ref><ref id="pone.0205119.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Casabianca</surname><given-names>A</given-names></name>, <name><surname>Gori</surname><given-names>C</given-names></name>, <name><surname>Orlandi</surname><given-names>C</given-names></name>, <name><surname>Forbici</surname><given-names>F</given-names></name>, <name><surname>Federico Perno</surname><given-names>C</given-names></name>, <name><surname>Magnani</surname><given-names>M</given-names></name>. <article-title>Fast and sensitive quantitative detection of HIV DNA in whole blood leucocytes by SYBR green I real-time PCR assay</article-title>. <source>Mol Cell Probes</source>
<year>2007</year>: <volume>21</volume>(<issue>5&#x02013;6</issue>):<fpage>368</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcp.2007.05.005</pub-id>
<?supplied-pmid 17629450?><pub-id pub-id-type="pmid">17629450</pub-id></mixed-citation></ref><ref id="pone.0205119.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Wensing</surname><given-names>AM</given-names></name>, <name><surname>Calvez</surname><given-names>V</given-names></name>, <name><surname>G&#x000fc;nthard</surname><given-names>HF</given-names></name>, <name><surname>Johnson</surname><given-names>VA</given-names></name>, <name><surname>Paredes</surname><given-names>R</given-names></name>, <name><surname>Pillay</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Update of the drug resistance mutations in HIV-1: international AIDS society-USA</article-title>. <source>Top Antivir Med</source> 2017: <year>2017</year>;<volume>24</volume>(<issue>4</issue>): [Epub ahead of print]</mixed-citation></ref><ref id="pone.0205119.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Tamura</surname><given-names>K</given-names></name>, <name><surname>Peterson</surname><given-names>D</given-names></name>, <name><surname>Peterson</surname><given-names>N</given-names></name>, <name><surname>Stecher</surname><given-names>G</given-names></name>, <name><surname>Nei</surname><given-names>M</given-names></name>, <name><surname>Kumar</surname><given-names>S</given-names></name>
<article-title>MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods</article-title>. <source>Mol Biol Evol</source>
<year>2011</year>: <volume>28</volume>(<issue>10</issue>):<fpage>2731</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/molbev/msr121</pub-id>
<?supplied-pmid 21546353?><pub-id pub-id-type="pmid">21546353</pub-id></mixed-citation></ref><ref id="pone.0205119.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Bansode</surname><given-names>V</given-names></name>, <name><surname>McCormack</surname><given-names>GP</given-names></name>, <name><surname>Crampin</surname><given-names>AC</given-names></name>, <name><surname>Ngwira</surname><given-names>B</given-names></name>, <name><surname>Shrestha</surname><given-names>RK</given-names></name>, <name><surname>French</surname><given-names>N</given-names></name>
<etal>et al</etal>
<article-title>Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra-deep pyrosequencing</article-title>. <source>BMC Infect Dis</source>
<year>2013</year>: <volume>13</volume>:<fpage>52</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2334-13-52</pub-id>
<?supplied-pmid 23363532?><pub-id pub-id-type="pmid">23363532</pub-id></mixed-citation></ref><ref id="pone.0205119.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Noe</surname><given-names>A</given-names></name>, <name><surname>Plum</surname><given-names>J</given-names></name>, <name><surname>Verhofstede</surname><given-names>C</given-names></name>. <article-title>The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance</article-title>. <source>J Antimicrob Chemother</source>
<year>2005</year>: <volume>55</volume>(<issue>4</issue>):<fpage>410</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dki038</pub-id>
<?supplied-pmid 15728140?><pub-id pub-id-type="pmid">15728140</pub-id></mixed-citation></ref><ref id="pone.0205119.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Yanik</surname><given-names>EL</given-names></name>, <name><surname>Napravnik</surname><given-names>S</given-names></name>, <name><surname>Hurt</surname><given-names>CB</given-names></name>, <name><surname>Dennis</surname><given-names>A</given-names></name>, <name><surname>Quinlivan</surname><given-names>EB</given-names></name>, <name><surname>Sebastian</surname><given-names>J</given-names></name>
<etal>et al</etal> (<year>2012</year>) <article-title>Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients</article-title>. <source>J Acquir Immune Defic Syndr</source> 2012: <volume>61</volume>(<issue>2</issue>):<fpage>258</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e3182618f05</pub-id>
<?supplied-pmid 22692092?><pub-id pub-id-type="pmid">22692092</pub-id></mixed-citation></ref><ref id="pone.0205119.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Fourati</surname><given-names>S</given-names></name>, <name><surname>Malet</surname><given-names>I</given-names></name>, <name><surname>Lambert</surname><given-names>S</given-names></name>, <name><surname>Soulie</surname><given-names>C</given-names></name>, <name><surname>Wirden</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>E138K and M184I mutations in HIV-1 reversetranscriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure</article-title>. <source>AIDS</source>
<year>2012</year>: <volume>26</volume>(<issue>13</issue>):<fpage>1619</fpage>&#x02013;<lpage>24</lpage>. <?supplied-pmid 22695298?><pub-id pub-id-type="pmid">22695298</pub-id></mixed-citation></ref><ref id="pone.0205119.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Chew</surname><given-names>CB</given-names></name>, <name><surname>Potter</surname><given-names>SJ</given-names></name>, <name><surname>Wang</surname><given-names>B</given-names></name>, <name><surname>Wang</surname><given-names>YM</given-names></name>, <name><surname>Shaw</surname><given-names>CO</given-names></name>, <name><surname>Dwyer</surname><given-names>DE</given-names></name>
<etal>et al</etal>
<article-title>Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART</article-title>. <source>J ClinVirol</source>
<year>2005</year>: <volume>33</volume>(<issue>3</issue>):<fpage>206</fpage>&#x02013;<lpage>16</lpage>.</mixed-citation></ref><ref id="pone.0205119.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Sanabani</surname><given-names>SS</given-names></name>, <name><surname>Pessoa</surname><given-names>R</given-names></name>, <name><surname>Soares de Oliveira</surname><given-names>AC</given-names></name>, <name><surname>Martinez</surname><given-names>VP</given-names></name>, <name><surname>Giret</surname><given-names>MTM</given-names></name>, <name><surname>de Menezes Succi</surname><given-names>RC</given-names></name>
<etal>et al</etal>
<article-title>Variability of HIV-1 genomes among children and adolescents from Sao Paulo, Brazil</article-title>. <source>PLoS One</source>
<year>2013</year>: <volume>8</volume>(<issue>5</issue>):<fpage>e62552</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0062552</pub-id>
<?supplied-pmid 23667488?><pub-id pub-id-type="pmid">23667488</pub-id></mixed-citation></ref><ref id="pone.0205119.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Saracino</surname><given-names>A</given-names></name>, <name><surname>Gianotti</surname><given-names>N</given-names></name>, <name><surname>Marangi</surname><given-names>M</given-names></name>, <name><surname>Cibelli</surname><given-names>DC</given-names></name>, <name><surname>Galli</surname><given-names>A</given-names></name>, <name><surname>Punzi</surname><given-names>G</given-names></name>
<etal>et al</etal>
<article-title>Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART</article-title>. <source>J Med Virol</source>
<year>2008</year>: <volume>80</volume>(<issue>10</issue>):<fpage>1695</fpage>&#x02013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21261</pub-id>
<?supplied-pmid 18712823?><pub-id pub-id-type="pmid">18712823</pub-id></mixed-citation></ref><ref id="pone.0205119.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Venturi</surname><given-names>G</given-names></name>, <name><surname>Romano</surname><given-names>L</given-names></name>, <name><surname>Carli</surname><given-names>T</given-names></name>, <name><surname>Corsi</surname><given-names>P</given-names></name>, <name><surname>Pippi</surname><given-names>L</given-names></name>, <name><surname>Valensin</surname><given-names>PE</given-names></name>
<etal>et al</etal>
<article-title>Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy</article-title>. <source>Antivir Ther</source>
<year>2002</year>: <volume>7</volume>(<issue>4</issue>):<fpage>245</fpage>&#x02013;<lpage>50</lpage>. <?supplied-pmid 12553478?><pub-id pub-id-type="pmid">12553478</pub-id></mixed-citation></ref><ref id="pone.0205119.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Yebra</surname><given-names>G</given-names></name>, <name><surname>de Mulder</surname><given-names>M</given-names></name>, <name><surname>del Romero</surname><given-names>J</given-names></name>, <name><surname>Rodriguez</surname><given-names>C</given-names></name>, <name><surname>Holguin</surname><given-names>A</given-names></name>. <article-title>HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability</article-title>. <source>Antiviral Res</source>
<year>2010</year>: <volume>85</volume>(<issue>2</issue>):<fpage>409</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.11.010</pub-id>
<?supplied-pmid 20004217?><pub-id pub-id-type="pmid">20004217</pub-id></mixed-citation></ref><ref id="pone.0205119.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Shet</surname><given-names>A</given-names></name>, <name><surname>Berry</surname><given-names>L</given-names></name>, <name><surname>Mohri</surname><given-names>H</given-names></name>, <name><surname>Mehandru</surname><given-names>S</given-names></name>, <name><surname>Chung</surname><given-names>C</given-names></name>, <name><surname>Kim</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience</article-title>. <source>J Acquir Immune Defic Syndr</source>
<year>2006</year>: <volume>41</volume>(<issue>4</issue>):<fpage>439</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1097/01.qai.0000219290.49152.6a</pub-id>
<?supplied-pmid 16652051?><pub-id pub-id-type="pmid">16652051</pub-id></mixed-citation></ref><ref id="pone.0205119.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Hamers</surname><given-names>RL</given-names></name>, <name><surname>Wallis</surname><given-names>CL</given-names></name>, <name><surname>Kityo</surname><given-names>C</given-names></name>, <name><surname>Siwale</surname><given-names>M</given-names></name>, <name><surname>Mandaliya</surname><given-names>K</given-names></name>, <name><surname>Conradie</surname><given-names>F</given-names></name>
<etal>et al</etal>
<article-title>HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study</article-title>. <source>Lancet Infect Dis</source>
<year>2011</year>: <volume>11</volume>(<issue>10</issue>):<fpage>750</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70149-9</pub-id>
<?supplied-pmid 21802367?><pub-id pub-id-type="pmid">21802367</pub-id></mixed-citation></ref><ref id="pone.0205119.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Geretti</surname><given-names>AM</given-names></name>, <name><surname>Conibear</surname><given-names>T</given-names></name>, <name><surname>Hill</surname><given-names>A</given-names></name>, <name><surname>Johnson</surname><given-names>JA</given-names></name>, <name><surname>Tambuyzer</surname><given-names>L</given-names></name>, <name><surname>Thys</surname><given-names>K</given-names></name>
<etal>et al</etal>
<article-title>Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz</article-title>. <source>J Antimicrob Chemother</source>
<year>2014</year>: <volume>69</volume>(<issue>4</issue>):<fpage>1090</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkt474</pub-id>
<?supplied-pmid 24284781?><pub-id pub-id-type="pmid">24284781</pub-id></mixed-citation></ref><ref id="pone.0205119.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Ghosn</surname><given-names>J</given-names></name>, <name><surname>Pellegrin</surname><given-names>I</given-names></name>, <name><surname>Goujard</surname><given-names>C</given-names></name>, <name><surname>Deveau</surname><given-names>C</given-names></name>, <name><surname>Viard</surname><given-names>J</given-names></name>, <name><surname>Galimand</surname><given-names>J</given-names></name>
<etal>et al</etal>
<article-title>HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time</article-title>. <source>AIDS</source>
<year>2006</year>: <volume>20</volume>(<issue>2</issue>):<fpage>159</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1097/01.aids.0000199820.47703.a0</pub-id>
<?supplied-pmid 16511408?><pub-id pub-id-type="pmid">16511408</pub-id></mixed-citation></ref><ref id="pone.0205119.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>YM</given-names></name>, <name><surname>Dyer</surname><given-names>WB</given-names></name>, <name><surname>Workman</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>B</given-names></name>, <name><surname>Peng</surname><given-names>NK</given-names></name>, <name><surname>Lachireddy</surname><given-names>K</given-names></name>
<etal>et al</etal>
<article-title>Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART</article-title>. <source>Curr HIV Res</source>
<year>2007</year>: <volume>5</volume>(<issue>2</issue>):<fpage>235</fpage>&#x02013;<lpage>50</lpage>. <?supplied-pmid 17346137?><pub-id pub-id-type="pmid">17346137</pub-id></mixed-citation></ref></ref-list></back></article>